G1 Therapeutics Inc
(NAS:GTHX)
$
7.15
0 (0%)
Market Cap: 377.22 Mil
Enterprise Value: 364.45 Mil
PE Ratio: 0
PB Ratio: 15.31
GF Score: 31/100 G1 Therapeutics Inc at B Riley Securities Oncology Conference (Virtual) Transcript
Jan 19, 2023 / 04:30PM GMT
Release Date Price:
$6.21
(-2.82%)
Andrew Fleszar
B. Riley Securities, Inc., Research Division - Research Analyst
Good morning, everyone, and welcome to the B. Riley Virtual Oncology Conference. I'm Andy Fleszar, part of the biotech team here at B. Riley, and I'm pleased to introduce our next company, G1 Therapeutics. With me, I have CEO, Jack Bailey; CSO, Raj Malik; and CCO, Andrew Perry. Jack, Raj, Andrew, thank you for joining us today.
John E. Bailey
G1 Therapeutics, Inc. - CEO, President & Director
Great to be here, Andy. Thanks for having us.
Questions & Answers
Andrew Fleszar;John E. Bailey
B. Riley Securities, Inc., Research Division - Research Analyst;
While the COSELA launch in small cells has been the primary focus for many investors, attention is starting to shift to your upcoming read-out in colorectal cancer. So let's start the discussion there. Maybe give us a brief overview of COSELA and what's the magnitude of the opportunity in colorectal cancer relative to extensive stage small cell.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot